Solar Biotech, Inc. /VA/

全球医疗行业每日重点资讯 文 | 苏丁 企业动态 全球牙科器械龙头Patterson Companies（帕特森）宣布，公司已达成最终协议，将被私募股权公司Patient Square Capital收购。这交易笔价值约41亿美元（约合299亿元人民币），Patterson公司的股东将获得每股31.35美元的现金。此次对Patterson的收购还包括对其应收账款融资安排的再融资，巩固了公司估值，彰显了明确的战略增长机遇。 旧金山生物科技公司Retro Biosciences正在筹集10亿美元资金，用于支持其通过人工智能（AI）技术延长人类寿命10年的使命。该公司计划今年将其首款药物推进临床试验阶段。Retro Biosciences的种子资金由OpenAI首席执行官萨姆·阿尔特曼提供，金额为1.8亿美元，而阿尔特曼还将在本轮A轮融资中追加投资。Retro Biosciences与OpenAI合作开发了一款定制AI模型，能够设计蛋白质，将普通细胞暂时转化为干细胞，从而逆转细胞衰老过程。 Beta Bionics公司公布IPO条款。这家致力于开发自动化胰岛素输送系统的企业计划通过发行750万股股票，以每股14至16美元的价格区间筹集1.13亿美元。此外，公司还计划通过向现有股东进行的并行私人配售额外筹资1700万美元。Beta Bionics的核心产品iLet仿生胰腺（iLet Bionic Pancreas）是首个获美国食品药品监督管理局（FDA）批准的胰岛素输送设备。 SOLARBIOTECH、GPC Bio和Eleszto Genetika宣布已完成收购并将在单一所有权下进行战略整合。此次合并打造了一个垂直整合的合成生物学和生物制造巨头，其在利用精准发酵的颠覆性潜力方面具有独特优势。统一后的公司完全有能力在生物制造的各个阶段为客户提供无与伦比的无缝支持，包括微生物菌种和生物工艺开发、工厂工程、自动化、建设、部署和大规模运营。三家公司的执行管理层将继续担任各自的领导职务。 产业动态 艾伯维（AbbVie）和Neomorph公司宣布达成一项合作及许可选择协议，双方将共同开发创新分子胶降解剂，针对肿瘤学和免疫学领域的多种靶点。根据协议条款，Neomorph将从艾伯维获得一笔预付款，并有资格获得高达16.4亿美元的里程碑付款。分子胶降解剂是一类创新小分子药物，可选择性靶向并触发导致癌症生长或免疫系统失调的蛋白质降解，从而提供一种更精确的治疗方法。 赛诺医疗于2024年8月向秘鲁医疗器械监管机构DIGEMID递交了SC HONKYTONKTM冠脉球囊扩张导管的注册申报资料，并于近日获得批准。该产品适用于冠状动脉狭窄节段或搭桥狭窄部位的球囊导管扩张，以改善心肌灌注。 安科锐宣布山东省肿瘤医院实现了一个里程碑：有100名患者使用Tomo C放射治疗系统完成治疗，该系统是通过中核集团与安科锐的合资企业在中国制造的产品。山东省肿瘤医院是中国第一家使用新Tomo C系统的医院，该系统已经通过扩大临床能力和为更多诊断癌症患者提供潜在治愈性治疗的机会证明了其价值。Tomo C系统旨在于为医疗护理团队提供放射治疗更大的确定性，让他们知道放射治疗所取得的结果。 我国首款猴痘疫苗正式启动临床试验。由国药集团中国生物上海生物制品研究所自主研发的MVA株猴痘减毒活疫苗I期临床研究启动会在河南省传染病医院召开，启动会围绕临床试验方案、临床现场操作要点和难点进行了充分的培训与讨论。该款猴痘疫苗于2024年9月9日，获得国家药品监督管理局签发的临床试验通知书，是我国首款获批临床的猴痘疫苗，有望在我国对猴痘病毒导致疾病的预防和控制中发挥重要作用。 印度细胞治疗公司Immuneel Therapeutics宣布CAR-T疗法（商品名：Qartemi）已获得印度监管机构中央药品标准管理组织 (CDSCO) 的批准上市，用于治疗成人B细胞非霍奇金淋巴瘤。这是全球首个用于治疗成人B细胞非霍奇金淋巴瘤 (B-NHL)的个性化精准CAR-T细胞疗法。 Molecular Devices高内涵成像系统迎来新成员——ImageXpress HCS.ai智能高内涵成像分析系统。该系统融合了先进的光学技术、直观的操作软件和强大的人工智能数据分析能力，无论是基础生物学研究、新疗法开发还是药物发现，无论是2D还是3D新模型，都能呈现优秀图像细节，提升整体实验效率，帮助研究人员获取全新见解。 联系美通社 +86-10-5953 9500 info@prnasia.com

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Catalent said it will manufacture Galapagos’ clinical-stage CAR T therapy, dubbed GLPG5101, for upcoming clinical trials. Manufacturing will be done at Catalent’s site in Princeton, NJ, according to the Tuesday release. Kindeva Drug Delivery’s subsidiary Meridian Medical Technologies has secured a $129 million contract to supply DuoDote, an antidote for a chemical nerve agent, to the US Strategic National Stockpile, the company said Jan. 16. Dr. Reddy’s reported 83.6 billion rupees ($967 million) in revenues for the three months ending December 2024, which is 4% up from the 7.1 billion rupees ($82 million) it reported for the same period last year, the company said Thursday. The US contributes to 40% of its quarterly revenue. Solarbiotech, GPC Bio and Eleszto Genetika are consolidating into one company to provide services in biomanufacturing, the companies said Wednesday. The consolidation brings together over 100 engineers, scientists and executives. Afrigen Biologics has received $6.2 million from the Coalition for Epidemic Preparedness Innovations to develop an mRNA vaccine for Rift Valley fever, the company said Monday. Rift Valley fever is spread by mosquitoes, with outbreaks mainly reported in sub-Saharan Africa. Eli Lilly and Merck are collaborating with Purdue University to launch a new manufacturing consortium called the Young Institute Pharmaceutical Manufacturing Consortium, according to a Friday release. It will use technology like AI to improve domestic manufacturing in the US. AGC Biologics will manufacture and supply lentiviral vectors to Adaptimmune for the company to use in its T-cell therapy letetresgene autoleucel, as announced Jan. 16. Genethon and Eukarÿs have partnered to develop a technology to cut the cost of making gene therapies, according to a Thursday release. Eukarÿs will provide its engineered enzyme, dubbed C3P3, and Genethon will design and manufacture AAV vectors and provide its biomanufacturing facilities. In the UK, Bells Healthcare is recalling 17 batches of its cough syrup medicines containing the API dextromethorphan hydrobromide, according to a Tuesday announcement. Foreign material was found in some bottles and was categorized as a Class 2 recall.

NORTON, Va., LA ROCHELLE, France and BUDAPEST, Hungary, Jan. 22, 2025 /CNW/ -- Today, SOLARBIOTECH, GPC Bio, and Eleszto Genetika proudly announced their acquisition and strategic unification under a single ownership. This consolidation creates a vertically integrated Synthetic Biology and Biomanufacturing powerhouse, uniquely positioned to harness the disruptive potential of precision fermentation. By integrating decades of expertise, the unified organization will leverage the strength of each team to seamlessly advance Synthetic Biology innovation from ideation to commercial production. The acquisitions bring together over 100 engineers, scientists, and seasoned biotech executives, marking a significant leap forward in the rapidly evolving biomanufacturing landscape. The unified organization is fully equipped to give clients unparalleled and seamless support in all stages of biomanufacturing, including microbial strain and bioprocess development, plant engineering, automation, construction, deployment, and large-scale operations. The coming months will involve further integrational activities to fully leverage the strength of the organization. Strategic Relevance said Alex Berlin, CEO of Pictor Biotech Inc. (d.b.a. SOLARBIOTECH). Zsolt Popsé, CEO of GPC Bio, added, "With " Lóránd Szabó, Managing Director of Eleszto Genetika Kft., stated, " Peter Rosholm, owner of EG, GPC Bio and Pictor Biotech (dba SOLARBIOTECH) emphasized:. About the Companies SOLARBIOTECH ("SBC"), based in Norton, VA, USA, offers world-class expertise in microbial and animal and plant cell precision fermentation and downstream processing across various scales. Leveraging 18 acres of industrial park infrastructure in Southwest Virginia, SBC consistently delivers innovative synthetic biology bioprocesses and products for its partners. GPC Bio ("GPC"), headquartered in La Rochelle, France, specializes in the design, automation, software control, engineering, and fabrication of biomanufacturing equipment for the biopharmaceutical, food tech, and beverage industries. For nearly two decades, GPC Bio has delivered state-of-the-art systems to some of the biggest names in industrial biotech and biopharma. Eleszto Genetika Kft. ("EG"), based in Budapest, Hungary, brings nearly two decades of expertise in R&D for advanced industrial microbial strains. EG's portfolio includes microbial strains from engineered yeasts, bacteria, and filamentous fungi for producing a wide range of biopharmaceuticals, nutraceuticals, and cosmeceuticals, supported by cutting-edge infrastructure in the heart of the European Union. For Further Information, Please Contact: SOURCE Pictor Biotech Inc. (dba SOLARBIOTECH), GPC Bio, and Eleszto Genetika